Health ❯ Medicine ❯ Pharmaceuticals

Drug Development

Clinical Trials Obesity Treatments Alzheimer's Disease Weight Loss Drugs Inflammatory Bowel Disease Weight Loss Treatments Pain Medication Muscle-Activating Compounds ERR Protein Activation Semaglutide Research and Development Amylyx Pharmaceuticals Drug Withdrawal Regulatory Updates Regulatory Approval Chemotherapeutic Drugs Gepotidacin Synthetic Biology Sildenafil Gleevec Synthesis Methods Malaria Treatment Sarepta Therapeutics COPD Treatment Quantum Computing in Medicine Experimental Drugs Leucovorin Bradykinin B2 Receptor Antagonists Synthetic Proteins Oncology Weight Loss Medications Cholesterol Medications Cancer Therapies Novo Nordisk Cholesterol Management Donidalorsen Psoriasis Treatment Existing Drugs FDA Approval Cancer Treatments

Lilly and Nimbus Strike Multi-Year AI Deal for Oral Obesity Drugs

The pact reflects a broader pivot to lower-cost oral alternatives to injectable GLP-1 treatments.

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

Sanofi Secures Global Rights to ADEL’s Alzheimer’s Antibody in Deal Worth Up to $1.04 Billion

Pharvaris’ Oral HAE Drug Deucrictibant Delivers Rapid Relief in Pivotal Phase 3

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

Merck’s Oral PCSK9 Pill Matches Injectables in Phase 3, Setting Up 2026 FDA Bid

FDA Reapproves GSK’s Blenrep for Multiple Myeloma in Narrow Combination Use

Novartis Ianalumab Meets Efficacy and Safety Goals in Phase 3 Sjögren’s Trials

GSK Closes $12 Billion Licensing Pact for Hengrui’s COPD Therapy and 11 Preclinical Assets

Cancer Drugs Reverse Alzheimer’s Pathology in Mice, Advance to Clinical Trials

Artificial Enzymes Designed by Computers Rival Natural Catalysts

AI-Designed Rentosertib Improves Lung Function in Phase IIa IPF Trial